Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.
Approval Alert | Osimertinib in Advanced EGFR-Mutated NSCLC
Advertisement
Advertisement
Trending on CancerNetwork
1
Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC
2
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
3
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors
4
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars
5
